Sangart

What Sangart does

Sangart is a privately held biopharmaceutical company founded in 1998 and headquartered in San Diego, California. According to its firmographic description, the company develops global scientific, clinical, and commercial oxygen-therapeutic agents — a specialized class of drugs designed to deliver oxygen to tissues in conditions such as ischemia, trauma, and sickle cell disease. The firm operates with an employee base of 51-100, consistent with a clinical-stage development organization building out regulatory, clinical operations, and pre-commercial functions.

The company has sustained itself through repeated institutional capital raises rather than product revenue. Between 2002 and 2012, Sangart completed at least ten disclosed funding rounds totaling over $294 million, with Jefferies Financial Group acting as the lead or sole disclosed investor in five of those rounds (2007, 2009, 2011, 2012) and contributing approximately $250 million of the total. ODIN Forvaltning participated as an early institutional backer in 2003. No commercial product launch, partnership agreement, or revenue-generating arrangement is documented in the available data.

The available input contains a substantial body of detail describing a Norwegian consumer-facing affiliate website operating as "Sangart.com," which is functionally and jurisdictionally distinct from the biopharmaceutical entity described in the firmographic record (Norwegian affiliate content site vs. U.S. clinical-stage biopharma). That Norwegian-website content has been treated as off-subject for the purposes of this analysis, which is grounded in the biopharmaceutical Sangart Inc. as defined by the firmographics and corroborated by the disclosed funding history.

Name

Sangart

Legal name

Sangart.com

Website

https://sangart.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Sangart is a privately held, clinical-stage biopharmaceutical company founded in 1998 in San Diego that develops oxygen-therapeutic agents for global scientific, clinical, and commercial use.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC) (HLAHAGAD)

akta.pro secondary industry

Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management (HLAKANAM)

Keywords

• Oxygen therapeutics
• Biopharmaceutical development
• Hemoglobin-based drugs
• Oxygen carriers
• Clinical stage biotechnology

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Affiliate Marketing Commissions: The website generates revenue through affiliate marketing by recommending financial products (credit cards, personal loans) and hotels, earning commissions when users click through or apply for products. The site features comparative content about credit cards (Santander products, Ikano Visa), personal loans (Telefinans, Skala Finans), and hotel bookings.

Distribution channels1 record

Marketing channels2 records

Core offering

Sangart is a biopharmaceutical company developing oxygen-therapeutic agents for global scientific, clinical, and commercial applications. The company is focused on hemoglobin-based oxygen carriers intended to deliver oxygen to tissues in medical settings. Its offering targets unmet needs in oxygen delivery for surgical, trauma, and critical care use cases.

Product overview

Sangart.com operates as a Norwegian consumer information website providing content about travel, accommodation, and personal finance products. The primary service featured is Gardermoen Hotel Bed & Breakfast, a 3-star hotel near Oslo Airport. The website aggregates and reviews third-party financial products (credit cards, personal loans) and provides travel recommendations for various destinations including Tønsberg, Budapest, London, and Berlin.

Differentiator

Problem solved

Functional benefit

Products and services

• Oxygen-therapeutic agents Hemoglobin-based pharmaceutical agents developed by Sangart for clinical and commercial use, intended to deliver oxygen to tissues in medical settings such as surgery, trauma, and critical care.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Broad incumbents

• Baxter International: Large medical-products incumbent with past presence in HBOC/plasma-derived blood substitutes and a current portfolio of surgical and critical-care products relevant to oxygen-therapeutic commercialization partners.
• Terumo BCT: Established blood-collection, processing, and cell-therapy equipment manufacturer; comparable adjacent incumbent whose commercial channels Sangart would target for oxygen-therapeutic commercialization.
• Grifols: Major blood-plasma products company with a commercial footprint in hospitals and transfusion centers; a plausible partner/acquirer for a complementary hemoglobin-based oxygen carrier such as Sangart's.
• CSL Behring: Global plasma and blood-product manufacturer with hospital critical-care franchises; an obvious strategic counterparty for Sangart's transfusion and ischemia indications.

Emerging players

• Hemosol BioPharma (defunct): Former Canadian hemoglobin-based oxygen carrier developer whose clinical setbacks are a reference point for Sangart's regulatory and clinical-execution risk profile.
• Biopure Corporation (defunct/HK acquisition): Historic HBOC developer (Oxyglobin / Hemopure) and instructive comparable whose regulatory and commercial trajectory illustrates the safety and reimbursement challenges any HBOC player including Sangart must navigate.
• Espero BioPharma: Specialty biopharma developing cardiovascular and critical-care products including bivalirudin and legacy cilastatin combinations; an emerging adjacent comparator in critical-care hospital therapeutics.
• Adventrx Pharmaceuticals (now Mast Therapeutics / Savara): Historic clinical-stage peer focused on hematologic and respiratory critical-care indications; useful comparable for clinical-trial execution and partnership dynamics relevant to Sangart.

Direct peers

• Prolong Pharmaceuticals: Clinical-stage developer of hemoglobin-based oxygen carriers (e.g., Sanguinate) for sickle cell and ischemic indications; directly comparable mechanism, indication focus, and clinical-stage profile to Sangart.
• Hemoglobin Oxygen Therapeutics LLC: Private developer of PEGylated hemoglobin-based oxygen carriers (OxyVita, etc.) targeting trauma and ischemic indications; the closest direct therapeutic-area and modality comparator to Sangart's MP4OX platform.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds10 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sangart